From these studies, we concluded that mTOR inhibitors exerted distinct anti-tumour effects in pancreatic cancer xenografts that were characterised by heightened activation of the PI3K/Akt/mTOR pathway. The gene discussed is PIK3CA; the disease is familial pancreatic carcinoma.